By Crispus Nyaga ,
54 minutes ago
Hims & Hers Health (NYSE: HIMS ) stock has lost momentum this year. After peaking at $72.78 in 2025, it has slumped about 65% to the current $26. The retreat has benefited investors betting against the company, with short interest rising to 23%. So, will the stock rebound or keep falling after its earnings?
Hims & Hers to Publish its Earnings as Short Interest Rises
Hims & Hers, a top player in the telehealth industry, has slumped in the past 12 months as the company has faced several challenges, especially in the weight loss industry. Recently, however, the firm has made deals with leading players in the GLP industry like Eli Lilly and Novo Nordisk.
In a statement last week, the company said that it would expand access to Eli Lilly’s Zepbound and Foundayo on its platform. Its customers will pay $149 a month for Foundayo and $299 a month for Zepbound.
The next important catalyst for Hims & Hers will be its financial results, which are expected to show that its revenue jumped in the third quarter. Its last results showed that its revenue rose by 38% in Q2 to $753 million, with its subscribers hitting 2.9 million. The company also hiked its annual re...